Next Article in Journal
Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env
Next Article in Special Issue
Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity?
Previous Article in Journal
Complete Genome Sequence, Genome Stability and Phylogeny of the Vaccine Strain Mycobacterium bovis BCG SL222 Sofia
Previous Article in Special Issue
Enterovirus A71 Vaccines
Review

Correlates of Vaccine-Induced Protection against SARS-CoV-2

by 1,2,3, 1,4,5,6, 1,2,3, 1,2,3,† and 1,2,3,*,†
1
Division of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany
2
German Centre for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20359 Hamburg, Germany
3
Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany
4
Excellence Centre for Medical Mycology (ECMM), 1st Department of Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany
5
Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Translational Research, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
6
German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 50937 Cologne, Germany
*
Author to whom correspondence should be addressed.
Authors contributed equally.
Academic Editor: Francisco Sobrino
Vaccines 2021, 9(3), 238; https://doi.org/10.3390/vaccines9030238
Received: 3 February 2021 / Revised: 1 March 2021 / Accepted: 4 March 2021 / Published: 10 March 2021
(This article belongs to the Special Issue Evaluation of Vaccine Immunogenicity)
We are in the midst of a pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19). SARS-CoV-2 has caused more than two million deaths after one year of the pandemic. The world is experiencing a deep economic recession. Safe and effective vaccines are needed to prevent further morbidity and mortality. Vaccine candidates against COVID-19 have been developed at an unprecedented speed, with more than 200 vaccine candidates currently under investigation. Among those, 20 candidates have entered the clinical Phase 3 to evaluate efficacy, and three have been approved by the European Medicines Agency. The aim of immunization is to act against infection, disease and/or transmission. However, the measurement of vaccine efficacy is challenging, as efficacy trials need to include large cohorts with verum and placebo cohorts. In the future, this will be even more challenging as further vaccine candidates will receive approval, an increasing number of humans will receive vaccinations and incidence might decrease. To evaluate novel and second-generation vaccine candidates, randomized placebo-controlled trials might not be appropriate anymore. Correlates of protection (CoP) could be an important tool to evaluate novel vaccine candidates, but vaccine-induced CoP have not been clearly defined for SARS-CoV-2 vaccines. In this review, we report on immunogenicity against natural SARS-CoV-2 infection, vaccine-induced immune responses and discuss immunological markers that can be linked to protection. By discussing the immunogenicity and efficacy of forerunner vaccines, we aim to give a comprehensive overview of possible efficacy measures and CoP. View Full-Text
Keywords: COVID-19; correlates of protection; immunogenicity; SARS-CoV-2; vaccine; pandemic COVID-19; correlates of protection; immunogenicity; SARS-CoV-2; vaccine; pandemic
Show Figures

Figure 1

MDPI and ACS Style

Koch, T.; Mellinghoff, S.C.; Shamsrizi, P.; Addo, M.M.; Dahlke, C. Correlates of Vaccine-Induced Protection against SARS-CoV-2. Vaccines 2021, 9, 238. https://doi.org/10.3390/vaccines9030238

AMA Style

Koch T, Mellinghoff SC, Shamsrizi P, Addo MM, Dahlke C. Correlates of Vaccine-Induced Protection against SARS-CoV-2. Vaccines. 2021; 9(3):238. https://doi.org/10.3390/vaccines9030238

Chicago/Turabian Style

Koch, Till, Sibylle C. Mellinghoff, Parichehr Shamsrizi, Marylyn M. Addo, and Christine Dahlke. 2021. "Correlates of Vaccine-Induced Protection against SARS-CoV-2" Vaccines 9, no. 3: 238. https://doi.org/10.3390/vaccines9030238

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop